Business context and reporting period
Entity mismatch: The filing is Flex Pharma, Inc.’s Form 10-K for the fiscal year ended December 31, 2015; it is not a filing for Decoy Therapeutics Inc. The company is a pre-revenue biotechnology and consumer-products company developing TRP-activator products for muscle cramps and spasms. Its 2015 comparison is with the period from its February 26, 2014 inception through year-end, not a full prior fiscal year.
Financial results and liquidity
| Metric | 2015 | Prior comparable period |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $12.7 million | $4.0 million |
| Selling, general and administrative expense | $16.5 million | $4.0 million |
| Operating loss | $29.2 million | $8.0 million |
| Net loss | $29.1 million | $8.0 million |
| Basic and diluted net loss per share | $2.08 | $4.57 |
| Net cash used in operating activities | $20.7 million | $6.5 million |
| Cash, cash equivalents and marketable securities at year-end | $93.7 million | $33.9 million |
The 2015 net loss included $6.6 million of non-cash stock-based compensation. Loss per share comparisons are affected by the substantially different weighted-average share counts following the February 2015 IPO. Margins are not meaningful because the company reported no revenue.
At December 31, 2015, total assets were $95.1 million, working capital was $89.4 million, total liabilities were $2.9 million and stockholders’ equity was $92.2 million. The company reported no long-term debt. Financing cash flow was $80.8 million, principally reflecting IPO proceeds; investing cash flow was a $27.3 million use, mainly net purchases of marketable securities.
Fourth-quarter 2015 net loss was $7.9 million, comprising $3.3 million of R&D expense and $4.6 million of SG&A expense. No quarterly revenue was reported.
Material changes versus the prior comparable period
- Operating expenses rose $21.2 million versus the partial 2014 inception period, reflecting expanded R&D and clinical work, increased headcount, consumer-brand development and public-company costs.
- Net cash used in operations increased to $20.7 million from $6.5 million. Year-end cash, cash equivalents and marketable securities increased following the $79.9 million of net IPO proceeds.
- All outstanding Series A and Series B preferred shares converted into common stock at the IPO. The company had 15.7 million common shares outstanding at year-end 2015 and reported 18.0 million outstanding as of March 4, 2016.
Outlook, commentary and key risks
Management estimated that existing cash and marketable securities would fund its current operating plan through mid-2018, while warning that this estimate depends on assumptions and spending could exceed expectations. The company expected to need additional funding to advance drug programs and support consumer-product commercialization; no committed external funding source was disclosed. The filing does not provide revenue or earnings guidance.
- Management expected a consumer beverage launch in the second quarter of 2016, initially targeting Los Angeles, Boulder and Boston, with online sales and specialty retail distribution. The company had not yet generated product revenue.
- Following a February 2016 study of 50 people with frequent nocturnal leg cramps, the company reported statistically significant results on several endpoints and no serious adverse events. This was a small study of an extract formulation under a dietary-supplement framework; results do not establish efficacy or approval of a drug candidate.
- For 2016, management expected another nocturnal-leg-cramp study and studies of FLX-787 in MS and ALS patients outside the United States. Drug candidates remained at an early development stage, and U.S. drug trials would require an IND and supporting preclinical work.
- Key risks include failure to replicate small-study results, uncertain regulatory treatment and permissible product claims, clinical and approval delays, dependence on third-party manufacturers and CROs, consumer acceptance of a premium-priced product, and potential need for further capital and shareholder dilution.
- The company is obligated to pay its founders an aggregate royalty of 2% of gross sales of qualifying products, in perpetuity. No material litigation was reported.
Important facts for investors to verify
- Confirm the filing’s issuer and period: this is Flex Pharma’s 2015 Form 10-K, despite the request metadata naming Decoy Therapeutics and 2015 Q4.
- Track whether the planned consumer launch occurred, the applicable regulatory classification and claims, and whether meaningful sales followed.
- Review subsequent clinical results, study sizes and endpoints, and the status of IND-enabling work and planned MS/ALS studies.
- Assess cash burn against the mid-2018 runway estimate, including commercialization and clinical spending, and whether additional financing was required.
- Consider the founders’ 2% gross-sales royalty, potential equity dilution and reliance on outside manufacturers and clinical vendors.